Microinvasive Cervical Cancer as a Model for Therapeutic De-Escalation in Gynecologic Oncology

Background: Microinvasive cervical cancer represents the earliest stage of stromal invasion and is associated with excellent oncological outcomes. Its clinical relevance arises from the potential disproportion between the limited extent of invasive disease and the morbidity of radical treatment, particularly in young women wishing to preserve fertility. Increasing evidence supports a transition from stage-based surgical radicality toward individualized, risk-adapted management. This narrative review critically examines microinvasive cervical cancer as a distinct clinical model of therapeutic de-escalation, with particular attention to the boundaries between evidence-supported conservative treatment and areas in which uncertainty persists. Methods: A narrative review of PubMed/MEDLINE was conducted for studies published between January 2010 and March 2026. Evidence concerning FIGO stages IA1 and IA2 was analyzed, focusing on diagnostic conization, pathological risk factors, lymphovascular space invasion (LVSI), margin status, histological subtype, fertility-sparing treatment, sentinel lymph node (SLN) assessment, ultrastaging, and follow-up. Studies including broader early-stage cervical cancer populations were considered only when stage IA results were separately available or clinically transferable to microinvasive disease, and were interpreted as indirect evidence when appropriate. Results: Accurate conization represents the cornerstone of the diagnosis and initial risk stratification of microinvasive cervical cancer, providing essential information on depth of stromal invasion, margin status, LVSI, histological subtype and multifocality. However, optimal risk assessment should integrate pathological findings with clinical staging, appropriate imaging and, when indicated, nodal assessment. FIGO stage alone does not adequately define individual risk, while imaging itself cannot reliably exclude occult small-volume nodal disease; therefore, the relative contribution of pathology, imaging and surgical nodal staging should be tailored to the individual risk profile. In FIGO IA1 disease without LVSI and with negative margins, conization alone provides excellent oncological control and lymph node staging is generally unnecessary. LVSI should be considered a risk modifier that may influence nodal assessment rather than an automatic indication for more radical cervical surgery. In IA1 with LVSI and IA2 disease, SLN biopsy may provide nodal staging with lower morbidity than systematic lymphadenectomy, although evidence specifically generated in microinvasive tumors remains limited. Fertility-sparing treatment is oncologically appropriate in carefully selected patients, whereas simple hysterectomy represents an adequate definitive option after completion of reproductive plans. Microinvasive adenocarcinoma requires specific consideration because of its endocervical location, potential multifocality, and the biological distinction between HPV-associated and HPV-independent histotypes. Major uncertainties remain regarding the prognostic significance of LVSI and low-volume nodal disease, the optimal indications for SLN assessment, and the limits of exclusive conservative treatment in IA2 disease. Conclusions: Microinvasive cervical cancer should not be regarded simply as the earliest anatomical stage of cervical cancer, but as a distinct clinical setting in which diagnostic precision may enable oncologically safe therapeutic de-escalation. The available evidence supports a shift from maximum surgical radicality toward the minimum effective treatment, provided that accurate histopathological assessment, appropriate patient selection, and specialized follow-up are ensured. Importantly, several recommendations for stage IA—particularly for IA2 disease and nodal management—still rely partly on evidence extrapolated from broader early-stage cervical cancer populations. Prospective multicenter studies and dedicated stage IA registries are therefore needed to define more precisely the boundaries within which therapeutic de-escalation can be safely applied.